Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques
- 271 Downloads
Escitalopram is used for post-partum depression; however, there are limited pharmacokinetic data of escitalopram in milk and plasma of infants breastfed by women taking the drug.
The objective of this study was to apply physiologically-based pharmacokinetic (PBPK) modelling to predict infant drug exposure (plasma area under the curve from time zero to infinity [AUC∞]) based on drug monitoring data of escitalopram in breast milk.
Using a newly developed liquid chromatography-tandem mass spectrometry (LC-MS/MS) method, we quantified escitalopram concentrations in milk samples of 18 breastfeeding women with escitalopram therapy at steady state, collected at three to five time points. The escitalopram concentrations in breast milk were used with infant feeding parameters from the literature to simulate infant daily dose. We used PK-Sim® to develop an adult PBPK model for escitalopram and extrapolated it to a population of 1600 infants up to 12 months of age. An integration of the simulated infant daily dose and the virtual infants with variable physiological–pharmacological parameters was used to predict drug exposure (plasma AUC∞) distribution in the population of infants breastfed by women receiving escitalopram 20 mg/day.
Escitalopram concentrations in milk were 50 ± 17 ng/mL (mean ± standard deviation). The simulated infant plasma AUC∞ following escitalopram exposure through breast milk was low, with a median of 1.7% (range 0.5–5.9%) of the corresponding maternal plasma AUC∞, indicating no substantial exposure.
Infant exposure levels to escitalopram in breast milk are low. A PBPK modeling approach can be used to translate data on drug monitoring in milk into a population distribution of infant plasma levels for drug safety assessment.
The authors would like to thank all the women who participated in this study, as well as the study coordinator, Sholeh Ghayoori, for recruiting participants, obtaining informed consent, sample collection and processing, and data management for this study.
This study was funded by the Canadian Institutes of Health Research, Grant no. DSA 263431.
Compliance with Ethical Standards
Conflicts of interest
Sarah R. Delaney, Paul R.V. Malik, Cristiana Stefan, Andrea N. Edginton, David A. Colantonio and Shinya Ito declare that they have no conflicts of interest that might be relevant to the contents of this article.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 18.Von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29(8):1102–9.Google Scholar
- 22.PK-Sim® Ontogeny Database Version 7.1. https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/master/PK-Sim%20Ontogeny%20Database%20Version%207.1.pdf. Accessed 16 Feb 2018.
- 24.Periclou A, Rao N, Sherman T, Ventura D, Abramowitz W. Single-dose pharmacokinetic study of escitalopram in adolescents and adults (abstract). Pharmacotherapy. 2003;10:1361–2.Google Scholar
- 25.Muñoz E, Ocampo D, Yepes N. Bioequivalence study of two formulations of escitalopram oxalate 20 mg tablets in healthy volunteers. J Bioequivalence Bioavailab. 2015;7(5):205–9.Google Scholar